NCT05319522

Brief Summary

This study will examine the relationship between circulating irisin and bone health individuals with spinal cord injury. Additionally, this study seeks to examine the influence of muscle fiber type on circulating irisin and identify an exercise-based means to increase irisin concentrations.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 8, 2022

Completed
1.1 years until next milestone

Study Start

First participant enrolled

May 5, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

July 11, 2025

Status Verified

July 1, 2025

Enrollment Period

2 years

First QC Date

March 31, 2022

Last Update Submit

July 8, 2025

Conditions

Keywords

Spinal cord injuriesIrisinBone mineral densityExercise

Outcome Measures

Primary Outcomes (3)

  • Irisin - Bone measure correlations

    Circulating irisin concentrations will be correlated with DXA and HR-pQCT bone measures

    Baseline; at rest

  • FNDC5 gene expression

    FNDC5 gene expression will be measured in vastus lateralis skeletal muscle biopsies via RT-PCR to determine if potential differences in circulating irisin concentrations may be attributed to differential gene expression.

    Baseline; at rest

  • Exercise induced change in irisin concentration

    Circulating irisin concentrations will be measured before and immediately following an arm ergometer high-intensity interval exercise bout to determine if this exercise modality can increased circulating irisin concentrations in individuals with SCI and controls

    baseline and immediately post-exercise

Study Arms (2)

Individuals with SCI

ACTIVE COMPARATOR

Male and female, Veteran and non-Veteran participants with traumatic SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.

Behavioral: Acute Exercise

Controls (No SCI)

ACTIVE COMPARATOR

Male and female Veterans, age and sex-matched to participants with SCI will complete the baseline blood draw, muscle biopsy and DXA/HR-pQCT bone imaging. This group will complete blood draws before and after arm ergometer high-intensity interval exercise bout.

Behavioral: Acute Exercise

Interventions

Acute ExerciseBEHAVIORAL

Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.

Also known as: Arm Ergometer Exercise; High-Intensity Interval Exercise
Controls (No SCI)Individuals with SCI

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants with SCI:
  • age 18 years or older
  • traumatic SCI at the cervical level 4 or lower that occurred at least 12 months prior to the start of the study
  • American Spinal Injury Association Impairment Scale A, B or C
  • uses a manual wheelchair as primary means of mobility (30+ hours per week)
  • is able to perform a transfer independently to and from a wheelchair
  • has adequate strength and upper extremity function to operate an arm ergometer
  • Control Participants:
  • age and sex-matched to participant with SCI

You may not qualify if:

  • Participants with SCI:
  • active use of medications which potentially affect bone metabolism, including: parathyroid hormone and analogs, androgenic or estrogenic steroids, bisphosphonates, oral glucocorticoids (use for more than 3 months)
  • history of fractures or dislocations in the upper extremity from which the participant has not fully recovered
  • upper limb pain or injury that interferes with the ability to perform aerobic exercise
  • recent hospitalization for any reason (within the past three months)
  • history of coronary artery disease, coronary bypass surgery or other cardiorespiratory events or conditions
  • likely to experience clinically significant autonomic dysreflexia and/ or orthostatic hypotension in response to vigorous exercise
  • endocrinopathy or metabolic disorders of the bone
  • e.g. Paget's disease, renal bone disease
  • history of allergic reaction to lidocaine
  • any other conditions that the person's primary care physician deems is a contraindication to participation in arm ergometry exercise stress testing or vigorous exercise
  • pregnant
  • participation in another "Greater than Minimal Risk" study.
  • Control Participants:
  • active use of medications which potentially affect bone metabolism, including: parathyroid hormone and analogs, androgenic or estrogenic steroids, bisphosphonates, oral glucocorticoids (use for more than 3 months)
  • +7 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Pittsburgh, Pennsylvania, 15240, United States

Location

MeSH Terms

Conditions

Spinal Cord InjuriesMotor Activity

Interventions

Exercise

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and InjuriesBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Adam J. Sterczala, PhD

    VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2022

First Posted

April 8, 2022

Study Start

May 5, 2023

Primary Completion

April 30, 2025

Study Completion

April 30, 2025

Last Updated

July 11, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations